Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 29511030

Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Clin Cancer Res
Publication date
2018 Jun 1
First author
van IJzendoorn DGP

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      van IJzendoorn DGP
      type
      Author
    2. name
      Sleijfer S
      type
      Author
    3. name
      Gelderblom H
      type
      Author
    4. name
      Eskens FALM
      type
      Author
    5. name
      van Leenders GJLH
      type
      Author
    6. name
      Szuhai K
      type
      Author
    7. name
      Bovée JVMG
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      van IJzendoorn DGP
      type
      Author
    2. name
      Sleijfer S
      type
      Author
    3. name
      Gelderblom H
      type
      Author
    4. name
      Eskens FALM
      type
      Author
    5. name
      van Leenders GJLH
      type
      Author
    6. name
      Szuhai K
      type
      Author
    7. name
      Bovée JVMG
      type
      Author
    bibliography ids
    1. nci-bib-2ea440a98467376a9a1717c9
    book metadata
    content sha256
    a90a1a49600bc53a5fc76b26f5e4b06e2032cf5efd0ac22ccfe2438a1ff79c4f
    document type
    citation
    dois
    1. 10.1158/1078-0432.CCR-17-3512
    electronic publication date
    display
    2018 Mar 6
    precision
    day
    year
    2018
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:29511030
    immutable id
    pubmed:29511030@a90a1a49600bc53a5fc76b26f5e4b06e2032cf5efd0ac22ccfe2438a1ff79c4f
    journal
    abbreviation
    Clin Cancer Res
    issn electronic
    1557-3265
    issn print
    1078-0432
    issue
    11
    name
    Clinical cancer research : an official journal of the American Association for Cancer Research
    nlm unique id
    9502500
    pages
    2678-2687
    volume
    24
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      29511030
      provenance
      batch id
      ec9444d0f4cade22eb9f
      provider
      NCBI PubMed ESummary
      record sha256
      4920f0d023809cb373120173a3e2218a3f2ad6bfaf1b03df8a4931d04ea633a9
      response sha256
      6eef0d8cc09b77e73af656f6390cc734befb84fbc4c229b886e81e5d95bece31
      retrieved at
      2026-09-09T23:47:30.975610+00:00
      publication date
      display
      2018 Jun 1
      precision
      day
      year
      2018
      publication types
      1. Journal Article
      2. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/29511030/
      title
      Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma.

      Preserved source evidence · Not medical advice